Amgen (AMGN) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over ...

The "Nebulizer Patent Landscape Report" report has been added to ResearchAndMarkets.com's offering. A comprehensive analysis ...

Blincyto's label has gradually been extended since 2014, and in December the MHRA approved it as the first immunotherapy for ...

BMS' Breyanzi and Amgen’s Blincyto will now be available to patients in England with certain types of blood cancer.

Telangana Chief Minister A. Revanth Reddy, Union Commerce and Industry Minister Piyush Goyal, G20 Sherpa Amitabh Kant and ...

Shares of Amgen Inc. AMGN advanced 1.24% to $297.93 Thursday, on what proved to be an all-around dismal trading session for ...

Eli Lilly Chief Scientific Officer Dan Skovronsky spoke to CNBC about obesity pills and more on the future of weight loss.

In the final days of 2024, three pharmaceutical giants sued the federal government. In their joint lawsuit, Amgen, Eli Lilly ...

During a live event, Alexander I. Spira, MD, PhD, and participants NGS testing practices and the rationale behind their ...

Pembrolizumab is a checkpoint inhibitor that binds to the protein PD-1 on T cells to help them recognize and attack invaders.